Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Aloe Blacc’s fame means nothing in biotech (and that’s the point)

From TechCrunch

By Theresa Loconsolo

April 15, 2026

Aloe Blacc’s fame means nothing in biotech (and that’s the point)

Aloe Blacc’s fame means nothing in biotech (and that’s the point)
Loading the player…

When Grammy-nominated singer-songwriter Aloe Blacc got COVID despite being vaccinated and boosted, he tried to fund research for a better solution. What he quickly found out? You can’t just write a check in biotech. Regulators require a commercialization plan, and philanthropy doesn’t move science through clinical trials or get you a license on university IP. Now, he’s bootstrapping a cancer drug platform targeting pancreatic cancer, a disease that kills 90% of its patients, and intentionally waiting to raise from his network until peer-reviewed papers can make his case. 

Watch as Aloe Blacc joins Rebecca Bellan on TechCrunch’s Equity podcast to talk about what happens when a creator decides to build instead of just invest, how Aloe is watching AI reshape both the biotech and music industries in real time, and his thoughts on who actually wins. 

Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod. 

View original article on techcrunch.com

Most Recent

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

AI-powered travel agency Fora hits unicorn status, raises $60M

AI-powered travel agency Fora hits unicorn status, raises $60M

Travel agency Fora announced a $60 million Series D round led by Forerunner and Tactile Ventures, valuing the company at $1 billion.

Jul 16, 2026

Sheryl Sandberg leads $10 million investment in AI-powered vehicle inspection service

Sheryl Sandberg leads $10 million investment in AI-powered vehicle inspection service

The startup, founded in 2021, lets enterprise customers use smartphones to scan and spot vehicle damage.

Jul 16, 2026

Similar Posts

The AI industry’s ‘next big bet,’ and should we just buy Chrome?

The AI industry’s ‘next big bet,’ and should we just buy Chrome?

Listen on Apple Podcasts Listen on Spotify The AI race is taking a detour as developers consider a new path to super-intelligent systems: test-time compute. Not sure what that means? Don’t worry, the Equity pod team breaks it down. Today, on TechCrunch’s Equity podcast, hosts Kirsten Korosec, Devin Coldewey and Margaux MacColl dig into the week’s tech and startup news, including what the new scaling method could mean for AI startups if it works and for chip providers if it fails. Listen to

Nov 22, 2024

Green flags for defense tech and Silicon Valley’s longevity obsession

Green flags for defense tech and Silicon Valley’s longevity obsession

Listen on Apple Podcasts Listen on Spotify This episode of Equity had so many themes: VC karaoke, the SpaceX economy, no moats for AI, OpenAI versus open source. You know it’s going to be good when the conversation between host Kirsten Korosec and fellow TCers Devin Coldewey and Margaux MacColl starts with the evergreen question: Is it ever OK to use a shirtless photo of yourself for your workplace Slack profile? Answer: yeah, nope. AI was a topic yet again at Equity. But it wasn’t just the

Sep 27, 2024

Promise Bio exits stealth backed by Pfizer and AstraZeneca

Promise Bio exits stealth backed by Pfizer and AstraZeneca

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring precision medicine to autoimmune diseases. Tel Aviv-based Promise Bio has developed a cloud-based AI platform that can spot different Post-Translational Modifications (PTMs) in proteins from a single blood sample. Before Promise’s tech, checking for one of these 200 protein modifications would require individua

Oct 23, 2024

AI’s tween years, who’s taking over climate tech, and the latest for Fearless Fund

AI’s tween years, who’s taking over climate tech, and the latest for Fearless Fund

Listen on Apple Podcasts Listen on Spotify What could be more frightening than Friday the 13th? How about a realization that AI is in its awkward tween stage? At least, it was for the TC Equity pod crew, which this week included hosts Devin Coldewey and Kirsten Korosec, along with TC reporters Tim De Chant and Dominic-Madori Davis. AI is often a topic here at Equity, and this week was no different. It seems to be everywhere — and nowhere — all at once. Take Apple, for instance. As Coldewey

Sep 13, 2024

Most Recent

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

AI-powered travel agency Fora hits unicorn status, raises $60M

AI-powered travel agency Fora hits unicorn status, raises $60M

Travel agency Fora announced a $60 million Series D round led by Forerunner and Tactile Ventures, valuing the company at $1 billion.

Jul 16, 2026

Sheryl Sandberg leads $10 million investment in AI-powered vehicle inspection service

Sheryl Sandberg leads $10 million investment in AI-powered vehicle inspection service

The startup, founded in 2021, lets enterprise customers use smartphones to scan and spot vehicle damage.

Jul 16, 2026

Similar Posts

The AI industry’s ‘next big bet,’ and should we just buy Chrome?

The AI industry’s ‘next big bet,’ and should we just buy Chrome?

Listen on Apple Podcasts Listen on Spotify The AI race is taking a detour as developers consider a new path to super-intelligent systems: test-time compute. Not sure what that means? Don’t worry, the Equity pod team breaks it down. Today, on TechCrunch’s Equity podcast, hosts Kirsten Korosec, Devin Coldewey and Margaux MacColl dig into the week’s tech and startup news, including what the new scaling method could mean for AI startups if it works and for chip providers if it fails. Listen to

Nov 22, 2024

Green flags for defense tech and Silicon Valley’s longevity obsession

Green flags for defense tech and Silicon Valley’s longevity obsession

Listen on Apple Podcasts Listen on Spotify This episode of Equity had so many themes: VC karaoke, the SpaceX economy, no moats for AI, OpenAI versus open source. You know it’s going to be good when the conversation between host Kirsten Korosec and fellow TCers Devin Coldewey and Margaux MacColl starts with the evergreen question: Is it ever OK to use a shirtless photo of yourself for your workplace Slack profile? Answer: yeah, nope. AI was a topic yet again at Equity. But it wasn’t just the

Sep 27, 2024

Promise Bio exits stealth backed by Pfizer and AstraZeneca

Promise Bio exits stealth backed by Pfizer and AstraZeneca

The first thing Promise Bio CEO Ronel Veksler wants you to know about the biotech company he co-founded is that it’s not another AI drug discovery company. Instead, he’s looking to bring precision medicine to autoimmune diseases. Tel Aviv-based Promise Bio has developed a cloud-based AI platform that can spot different Post-Translational Modifications (PTMs) in proteins from a single blood sample. Before Promise’s tech, checking for one of these 200 protein modifications would require individua

Oct 23, 2024

AI’s tween years, who’s taking over climate tech, and the latest for Fearless Fund

AI’s tween years, who’s taking over climate tech, and the latest for Fearless Fund

Listen on Apple Podcasts Listen on Spotify What could be more frightening than Friday the 13th? How about a realization that AI is in its awkward tween stage? At least, it was for the TC Equity pod crew, which this week included hosts Devin Coldewey and Kirsten Korosec, along with TC reporters Tim De Chant and Dominic-Madori Davis. AI is often a topic here at Equity, and this week was no different. It seems to be everywhere — and nowhere — all at once. Take Apple, for instance. As Coldewey

Sep 13, 2024